Tumor-associated trypsin inhibitor in pancreatic diseases.
We have evaluated tumor-associated trypsin inhibitor (TATI) as a marker for pancreatic and hepatic cancer. Of the patients studied 52 had pancreatic cancer, 30 primary liver cancer, 32 chronic pancreatitis, 25 biliary tract inflammatory disease, and 28 liver cirrhosis. A considerable number of falsely elevated values were observed in benign biliary diseases and in chronic relapsing pancreatitis. In pancreatic cancer the sensitivity of TATI was 63% while that of CEA was 40% and of CA19-9 77%. TATI is a marker of pancreatic disease but it does not differentiate between pancreatitis and pancreatic cancer. In liver cancer TATI and AFP has similar sensitivity and specificity.
Aroasio
E
E
Divisione di Gastroenteriologia, Osp. S. Giovanni Battista, Sede Molinette, Torino.
Piantino
P
P
D015295:Antigens, Tumor-Associated, Carbohydrate / Q000097:blood; D014408:Biomarkers, Tumor / Q000097:blood*; D002272:Carcinoembryonic Antigen / Q000097:blood; D006801:Humans; D008113:Liver Neoplasms / Q000097:blood / Q000175:diagnosis*; D010182:Pancreatic Diseases / Q000097:blood / Q000175:diagnosis*; D010190:Pancreatic Neoplasms / Q000097:blood / Q000175:diagnosis*; D011237:Predictive Value of Tests; D014359:Trypsin Inhibitor, Kazal Pancreatic / Q000097:blood*; D000509:alpha-Fetoproteins / Q000032:analysis
D015295:Antigens, Tumor-Associated, Carbohydrate; D014408:Biomarkers, Tumor; D002272:Carcinoembryonic Antigen; D000509:alpha-Fetoproteins; D014359:Trypsin Inhibitor, Kazal Pancreatic